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Abstract
The presence of ascites is one of the general ovarian cancer (OC) symptoms detected at 
initial diagnosis and can be present at an early stage but is most often seen in advanced 
disease. In newly diagnosed OC patients, ascites is treated by the standard treatment 
for the underlying disease. However, once the chemoresistant and recurrent features of 
the disease develop, management of a large volume of ascites can be a major problem. 
By increasing abdominal pressure, ascites can cause severe symptoms; thus, palliation 
of symptomatic patients is the main goal. The elimination of fluid accumulation in OC 
patients with these symptoms will certainly improve their quality of life and may even 
prolong survival. Unfortunately, no standard treatment for OC-associated ascites exists. 
There are several traditional therapies for ascites, with limited effectiveness and signifi-
cant adverse effects. Catumaxomab is the only medicine approved for intraperitoneal 
treatment of malignant ascites in patients with EpCAM-positive carcinomas. Advances in 
our understanding of malignant ascites aetiology and more effective treatment strategies 
for ascites and OC will help reduce the symptoms associated with ascites.
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1. Introduction
Ascites is an abnormal accumulation of serous fluid (>50 mL) in the peritoneal cavity between 
the membrane lining the abdominal wall and the membrane covering the abdominal organs. 
Although ascites is most commonly observed in patients with cirrhosis, 7–10% of patients 
with ascites develop it secondary to malignancy. The commonest primary tumour associ-
ated with the development of ascites is ovarian cancer (OC) [1]. Large amounts of ascites in 
a patient with OC usually indicate the presence of peritoneal metastasis; therefore, ascites 
is found in the majority of patients (89%) with advanced disease (FIGO stages III and IV). 
However, the absence of ascites may not exclude malignant disease, since ascites is rarely 
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(17%) observed in the early disease (FIGO stages I and II) and is absent in nearly half of 
borderline tumours. Unlike in primary OC, recurrent disease is not strongly associated with 
ascites, which was found in 38% of patients with recurrent OC [2].
Throughout history, ascites has always been regarded as a poor prognostic sign. In the 1700s, 
Sir Thomas Spencer Wells wrote “surgeons stood and trembled on the brink of ovarian 
waters” [3]. Studies addressing the prognostic significance of ascites in patients with stage III 
or IV have shown a significantly poorer survival [4]. Ascites is also associated with pharma-
coresistance [4]. Patch et al. showed that matched primary ascites (tumour cells isolated from 
ascites) share most genomic changes of acquired resistance with primary tumour samples 
across the whole genome [5].
In newly diagnosed ovarian cancer patients, ascites is treated by using the standard treatment 
for the underlying disease. However, once the chemoresistant and recurrent features of the 
disease develop, management of a large volume of ascites can be a major problem. Palliation 
of symptomatic patients is therefore the foremost goal, and elimination of fluid accumulation 
in patients with these symptoms will certainly improve their quality of life and may even pro-
long survival [6, 7]. An understanding of malignant ascites aetiology is of utmost importance 
if more effective treatment strategies for ascites and OC are to emerge in the future.
This chapter considers the aetiology and pathophysiology of malignant ascites in OC as well 
as current diagnostic modalities and explores the best form of management.
2. Mechanisms of malignant ascites formation
The word ascites originates from the ancient Greek askos, meaning a sac or bag. Celsus 
(c.30 BC–c.50 AD) postulated a link between ascites and renal disease, and he coined the 
term [8]. The peritoneal cavity, located between the parietal and visceral peritoneum, contains 
approximately 100 mL of serous fluids. Free fluid in the peritoneal cavity acts as a lubricant of 
the serosal surfaces and originates from the transduction of plasma through capillary mem-
branes of the peritoneal serosa. Healthy women may normally have as much as 20 mL of 
free peritoneal fluid, depending on the phase of the menstrual cycle [9]. Under physiological 
conditions, transudation is balanced by efflux of the peritoneal fluid via lymphatic vessels. 
Tumour growth eventually disrupts the normal regulation of intraperitoneal fluid flow and 
the maintenance of a steady state in the peritoneal cavity by simultaneously causing a greater 
fluid inflow and a reduced outflow. Four major factors that contribute to the formation of asci-
tes: two cause increased influx due to tumour-related factors and two cause decreased efflux 
due to lymphatic obstruction and mechanical obstruction by accumulation of tumour cells at 
the peritoneal surface (Figure 1) [1, 10]. The percentage of cases with a greater ascites volume 
increased as the stage of ovarian malignancy progressed [1].
2.1. Efflux from the peritoneal cavity into the blood
The peritoneal lymphatic system collects excess fluid, proteins, other macromolecules (>16 kDa) 
and cells and returns them to systemic circulation [11]. Decreased efflux from the peritoneal cav-
ity due to lymphatic obstruction by tumour cells was first proposed as a hypothesis for ascites 
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formation by Holm-Nielsen more than 60 years ago [12]. Published data using lymphoscintig-
raphy showed that patients with malignant ascites had no activity above the diaphragm after 
intraperitoneal injection of the isotope, in contrast to control patients with no ascites or cirrhotic 
ascites. Bronskill et al. [13] showed that OC patients with persistent, intractable ascites, who 
were approaching their terminal illness, had low peritoneal drainage rates (below 50 ml/h). This 
result generally indicates obstruction of the diaphragmatic plexus [13]. Initial events that lead to 
fluid accumulation were studied by Nagy et al. [14] who showed that in mice efflux the perito-
neal cavity of 125I-labelled human serum albumin and 51Cr-labelled red blood cells is markedly 
reduced (fivefold) within 1 day of i.p. ovarian tumour cell line injection. A significant reduction 
preceding a detectable increase in tumour cell number was not attributable to the blockage of 
peritoneal lymphatics by tumour cells and by itself did not provoke peritoneal fluid accumula-
tion. These results suggest a prominent role for nonobstructive mechanisms, including con-
traction of lymph vessels induced by secretion of tumour cell product(s). At later periods, the 
absorption of fluid from the peritoneal cavity might also be affected due to carcinomatosis [14].
2.2. Influx into the peritoneal cavity
Nagy et al. studied the influx of fluid into the peritoneal cavity of mice [14]. They found that 
after i.p. ovarian tumour cell line injection, influx of 125I-labelled human serum albumin rose 
between days 5 and 7 to values 13- to 25-fold higher than control values, when the tumour cell 
number had increased >500-fold. By day 10, influx had increased sufficiently to exceed efflux, 
Figure 1. Aetiology of malignant ascites in ovarian cancer.
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resulting in net accumulation of fluid [14]. An increase in influx is a result of various factors: 
(1) increased capillary permeability, (2) angiogenesis, (3) increased area for filtration and (4) 
decreased oncotic pressure difference. In malignant ascites, various factors secreted by tumour 
cells are present, which increase vascular permeability and induce angiogenesis. An early step 
leading to angiogenesis is partial proteolysis of vascular basal lamina, resulting in hyperper-
meability. Vascular endothelial growth factor (VEGF) is the most potent and specific angio-
genic factor, secreted by a large variety of tumours, peritoneal mesothelial cells, monocyte/
macrophages in malignant ascites and even tumour-infiltrating T cells [7]. Additionally, VEGF 
increases the permeability of vessels to plasma proteins, including albumin and fibrinogen, 
with a potency 10,000 times higher than histamine [15, 16]. Other factors that may also induce 
angiogenesis have been identified in malignant ascites and include basic fibroblast growth 
factor (bFGF), angiogenin, transforming growth factor alpha and beta (TGF-alpha, TGF-beta), 
interleukin-8, placental growth factor (PIGF) and platelet-derived endothelial cell growth fac-
tor (PD-EGF) [11]. Influx into the peritoneal cavity after i.p. ovarian tumour cell line injection 
rose significantly when the surface area for filtration also increased; the size and number of 
vessels lining the peritoneal cavity increased as much as 15-fold [16]. The protein content of 
malignant ascites is greater than in peritoneal fluid of healthy women [11]. The oncotic pressure 
difference between plasma and ascites therefore decreases, and as a consequence, reabsorption 
decreases and interstitial fluid accumulation results [11]. Liver metastasis causing hepatic vein 
obstruction may be an important aetiology factor in some cases of malignant ascites [1].
3. Diagnosis
The absence of symptoms or the presence of symptoms that mimic other conditions often 
results in diagnostic delay with OC, and this worsens prognosis. Evaluation consists of 
physical examination, imaging [ultrasonography, computerized tomography (CT), magnetic 
resonance image (MRI)], serum tumour markers analysis and ascitic fluid analysis (visual 
inspection, biochemical analysis, cytology and tumour markers). Diagnostic laparoscopy is 
an additional investigation and may be useful in patients with whom simple investigations 
have failed to determine the cause of ascites (Figure 2) [6, 17–21].
3.1. Symptoms
The most common complaint in the presentation of OC is abdominal swelling or bloating 
[17]. These symptoms are commonly associated with the physical and surgical finding of 
ascites. As the amount of fluid increases, ascites can cause significant symptoms referable to 
the gastrointestinal and genitourinary tracts. Malignant ascites is associated with abdominal 
and pelvic pain, while liver disease tends to be relatively painless [6, 17].
3.2. Imaging
Transabdominal and transvaginal ultrasonographies are the most sensitive techniques 
for the detection of ascitic fluid (Figure 3) [19]. Uncomplicated ascites appears as ahomo-
geneous, freely mobile, anechoic collection in the peritoneal cavity that demonstrates deep 
acoustic enhancement. Generally, free ascites do not displace organs situated between them 
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(Figure 3A) [20]. Sometimes, bowel loops do not float freely but may be tethered along the 
posterior abdominal wall, plastered to organs or surrounded by loculated fluid collections 
(Figure 3B) [21]. When small amounts of ascitic fluid localise in the Morison pouch and the 
pouch of Douglas, CT scan demonstrated the best sensitivity [21, 22].
3.3. Ascitic fluid analysis
In patients with new-onset ascites of unknown origin, peritoneal fluid analysis may provide 
some information regarding the origin of the disease. However, it remains difficult to differen-
tiate malignant ascites from other types [23].
On inspection, most ascitic fluids are transparent and tinged yellow. In the case of malig-
nancy, it could also appear pink or red (when at least 10,000 red blood cells/μL are present). 
Any inflammatory condition can cause an elevated white blood cell count. In case of malig-
nant ascites, lymphocytes usually predominate [24].
Conventional cytological examination shows high specificity, but its sensitivity is low (58–
75%) [23]. The cellular components of malignant ascites contain a complex mixture of cell 
populations, including tumour cells and stromal cells [25]. Immunohistochemistry (ICH) 
staining and cytological diagnosis by using cell block (CB) sections prepared with the ascites 
cytological specimen are useful in delineation of the primary origin of the tumour cells. Since 
Figure 2. Diagnostic laparoscopy showing ascites and peritoneal carcinosis.
Figure 3. Ultrasound images of ascites. (A) Transabdominal ultrasound image demonstrates ascites and ovarian tumour. 
(B) Transvaginal ultrasound image demonstrates ascites and intestinal carcinosis.
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multiple sections can be obtained by the CB method, this technique is particularly valuable 
when the ICH staining is required for a battery of markers. Typically, primary ovarian epithe-
lial cancers are positive for ER/PR, PAX8, CK7 and negative for CK20 and CDX2. The reverse 
is true for gastrointestinal cancers. By using a combination of cytological conventional smears 
and CB methods, the primary site could be detected with 81% accuracy [26, 27].
A number of soluble factors are present in abundance in malignant ascites, but few have been 
validated for their biomarker potential [28].
4. Treatment
Many factors influence the optimal therapeutic interventions. The aim is palliation in a signifi-
cant number of patients; only in a selected subgroup is it to improve survival [29].
4.1. Non-pharmacological treatment of ascites
Surgical treatment of malignant ascites involves a variety of different options, each with a 
certain degree of efficacy but not without risks [30]. Very few studies concern the benefits and 
harm of differing surgical interventions for intra-peritoneal fluid drainage. Numerous ques-
tions, such as how long should the drain stay in place, whether the volume of fluid drained 
should be replaced intravenously, whether the drain should be clamped to regulate the 
drainage of fluid and whether any particular vital observations should be regularly recorded, 
remain partially unanswered [31]. The most common surgical option for ascites drainage is 
abdominal paracentesis followed, in recent years, by the insertion of permanent tunnelled 
catheters (PleurX®) and peritoneal-venous shunts.
4.1.1. Paracentesis
Paracentesis (needle drainage of fluid) is an effective and widely used procedure for the man-
agement of treatment-resistant, recurrent malignant ascites [32]. It can provide good short-
term symptomatic relief in up to 90% of hospital cases, although it may also be offered as a 
day-case procedure [33].
The procedure involves the placement of a fine tube into the peritoneal cavity to drain ascitic 
fluid. The procedure can be done all at once but, especially for large volume paracentesis, the 
catheter can remain in place for several hours and sometimes for days [31]. The volume of 
drained fluid can vary according to the patient’s general conditions, from a few litres up to a 
maximum of 20 l [30]. Complications of the procedure may include peritonitis, sepsis, visceral 
injuries, bleeding and fluid leak. Moreover, especially for large volume drainage or repeated 
procedures, paracentesis may be associated with significantly higher incidence of hypoten-
sion and renal impairment [32, 34].
In general, intravenous fluid replacement is not routinely required for paracentesis with less 
than 5 l removed, but it depends on the patient’s clinical condition [32]. However, some reports 
suggest the use of 5% dextrose infusion during the procedure to avoid severe hypotensive 
episodes [30, 34]. There is no evidence albumin infusion is of benefit during paracentesis for 
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malignant ascites, even though many studies focusing on cirrhosis related ascites have dem-
onstrated great benefits of albumin infusion (6–8 g per litre of ascites removed) to maintain 
intravascular volume [30].
4.1.2. Peritoneal-venous shunting
Common peritoneal-venous shunts drain ascites from the peritoneal cavity into the superior 
vena cava and have a one-way valve that prevents reflux of blood [32, 34]. They are rarely 
used due to the high rate of complications such as occlusion, infection, coagulopathy and 
the widespread dissemination of malignant cells [35]. The only advantage compared to other 
techniques is related to saving electrolytes and proteins, preserving the body fluid balance 
[30, 32]. Two shunts are commonly used: the older LeVeen and the most recent Denver shunt, 
which require different pressures to open the valves [32, 36].
Contraindications of shunt positioning are as follows: congestive heart disease or renal failure 
due to the significant hemodilution and blood volume overload produced by the shunt, portal 
hypertension, and severe pleural effusion and clotting disorders [35].
A novel type of technique, automated low-flow ascites pump, drains ascites from the perito-
neal cavity to the bladder. This novel device seems effective (even though tested only on liver 
disease patients) for symptom relief, although data about safety (especially linked to catheter 
dislodgement and infections) are only preliminary [37].
4.1.3. Catheter drainage
In cases of recurrent or refractory malignant ascites, when frequent paracentesis is required, 
patients may benefit from an indwelling catheter [32]. This device allows easy and self-drain-
age, eliminating the need for hospitalisation and frequent paracentesis. The most common 
permanent catheters are the tunnelled PleurX®, Tenckhoff, Port-a-Cath and cope-type loop 
catheters [30, 38]. Most authors prefer tunnelled catheters due to greater stability (higher 
long-term patency rate and success rate) and lower infection rate [30, 39]. Recent trials have 
suggested that untunnelled catheters have a 21–34% risk of developing peritonitis compared 
to 4.4% with tunnelled Tenckhoff and 2.5% for tunnelled PleurX® [30].
Catheter placement can be performed with ultrasound guidance or with CT guidance in cases 
of particular anatomical conditions or widespread carcinomatosis [30]. Antibiotic prophy-
laxis is recommended for catheter placement [39]. Patients should be instructed to drain the 
fluid frequently enough to avoid the development of tense ascites, usually once or twice per 
week. Intravenous fluid replacement and/or albumin supplementation is indicated according 
to clinical conditions and ascites volume [30, 39].
The safety and cost-effective profiles of tunnelled catheters for the management of recurrent 
malignant ascites have been demonstrated by several observational studies [38, 40].
4.2. Pharmacological treatment of ascites
If the patient’s malignant disease is sensitive to chemotherapy, reduction of ascites produc-
tion and relief of symptoms may be achieved. However, most patients with ascites have 
already been treated with several lines of treatment, and their disease has become refractory 
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to chemotherapy, and carcinomatosis may not be amenable to surgery. For such patients, no 
pharmacological therapy has been approved except catumaxomab in the EU. The effective-
ness of other drugs to treat ascites has been explored in a few studies, with the majority of 
treatments having been studied in a small series.
4.2.1. Catumaxomab
Catumaxomab (Removab®; Fresenius Biotech) was approved in 2009 by the European 
Medicine Agency (EMA) for the intraperitoneal treatment of malignant ascites in adults with 
EpCAM-positive carcinomas, where standard therapy is not available or no longer feasible 
[41]. Catumoxomab is a trifunctional rat-mouse hybrid monoclonal antibody that is spe-
cifically directed against the epithelial cell adhesion molecule (EpCAM) and CD3 antigen 
(Figure 4). EpCAM (CD326) antigen is overexpressed in epithelial ovarian cancer of serous 
(68%), endometrioid (82%), clear cell (92%) and mucinous (49%) histological subtypes. EpCAM 
correlates with lower overall survival [42]. Over 80% of ovarian cancer patients have EpCAM 
over-expressed in tumour cells present in ascites [43]. EpCAM has been reported to initiate 
cell proliferation by upregulating the oncogene c-myc and to dampen antitumour immunity 
by blocking antigen presentation in dendritic cells [44, 45]. Mesothelial cells do not express 
EpCAM on their surface, so catumaxomab applied to the peritoneal cavity specifically targets 
epithelial tumour cells but not the normal tissue. CD3, as a second antigen, is expressed in 
mature T-cells as a component of the T-cell receptor. A third functional binding site in the 
Fc-region of catumaxomab enables the interaction with accessory immune cells (macrophages, 
dendritic cells and NK cells) via Fcγ receptors. Due to catumaxomab’s binding properties, 
tumour cells and immune effector cells come in close proximity, and complex “crosstalk” 
Figure 4. Schematic structure of catumaxomab.
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between the T cell and accessory cell can occur, which includes cytokines and co-stimulatory 
signalling necessary for T-cell activation cascade, resulting in the killing of tumour cells [41].
The clinical efficacy of catumaxomab in the treatment of malignant ascites has been dem-
onstrated in two clinical studies: a phase I/II study (STP-REM-01) and a pivotal phase II/III 
study (IP-REM-AC-01) [41]. In the first study treatment resulted in a significant reduction of 
the ascites flow rate from a median of 105 mL/h at baseline to 23 mL/h 1 day after the fourth 
infusion. Twenty-two of 23 patients did not require paracentesis between the last infusion 
and the end of the study. Tumour cell-count monitoring revealed a mean reduction up to 
99.9% of EpCAM-positive malignant cells in ascites. In a pivotal study, 129 ovarian cancer 
patients with recurrent symptomatic malignant ascites were randomised to treatment with 
catumaxomab (as four 6-h i.p. infusions on days 0, 3, 7, and 10 at doses 10, 20, 50, and 150 μg, 
respectively) plus paracentesis or paracentesis alone (the control group). The median time to 
the next paracentesis was significantly longer for catumaxomab plus paracentesis than para-
centesis alone: 77 versus 13 days (P < 0.0001) [41].
The safety profile of catumaxomab was established from five completed studies (STP-
REM-01, IP-REM-AC-01, IP-REM-PC-01-DE, AGO-Ovar-2.10 and IP-REM-PK-01-EU) [41]. A 
total of 258 patients were treated with i.p. administration of catumaxomab and 207 (80%) 
patients completed treatment, underlining the good tolerability for the drug. Catumaxomab 
may cause symptoms related to local and systemic cytokine release: pyrexia, nausea and 
vomiting. In 48% of patients, abdominal pain was reported, which is considered in part a 
consequence of the i.p. route of administration. All mentioned adverse drug reactions (ADRs) 
are fully reversible. One hundred and twenty-seven (49%) patients had at least one ADR of 
grade 3/4, according to the Terminology Criteria for Adverse Events (CTCAE). Abdominal 
pain, pyrexia and vomiting were the most common symptomatic grade 3 ADRs. Grade 4 
ADRs were isolated cases (1%), mostly related to the progression of the underlying malignant 
disease, such as ileus. In 1% of patients, symptoms of systemic inflammatory response syn-
drome (SIRS) were observed within 24 h after catumaxomab infusion, such as tachycardia, 
fever and dyspnea. These reactions resolve under symptomatic treatment. Conditions such as 
hypovolemia, hypoproteinaemia, hypotension, circulatory decompensation and acute renal 
impairment must be resolved before each infusion. Since patients with severe hepatic or renal 
impairment have not been investigated, treatment of these patients should only be considered 
after a thorough evaluation of benefit/risk. Catumaxomab is potentially immunogenic when 
administered to humans. In clinical studies, almost all patients (94%) developed human anti-
mouse antibodies (HAMAs) or human anti-rat antibodies (HARAs) 1 month after the last 
infusion; however, patients who developed HAMAs 8 days after the fourth infusion showed 
a better clinical outcome as measured by puncture-free survival, compared with HAMA-
negative patients, suggesting that HAMA development may be a biomarker for catumax-
omab response. No hypersensitivity reactions were observed [41].
4.2.2. Other immunological approaches
Evidence to suggest that an immunological approach to the treatment of malignant ascites in 
OC may be effective and has been observed in small studies of intraperitoneal administration 
of triamcinolone (long acting corticosteroid), interferons and TNFα [10, 46].
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Interferon alpha-2b (IFNα-2b), administered i.p. inserted with a 9-French catheter, was evalu-
ated in a study by Sartory et al. Twelve of 41 patients had OC. A complete response (no fluid 
recurrence) within 30 days of treatment (six courses with an interval of 4 days with six or nine 
million units depending on a body weight) occurred in 65% of OC patients. The fluid reaccu-
mulated after 11.4 days before and 70.5 days after the treatment. Adverse effects were flu-like 
symptoms, vomiting and infection with staphylococcus (two patients). If there is no response 
after the first three courses, the treatment should be stopped [47].
TNFα, installed inside the abdomen of advanced OC patients for 24–48 h (the procedure was 
repeated on day 8 at a dose of 0.08–0.014 mg/m2), was evaluated in a study by Kaufmann et al. 
Production of ascites was supressed or reduced to a minimum for at least 4 weeks in 87% of 
patients. The treatment was not effective in patients with malignant ascites due to mucinous 
OC. Patients often suffer from flu-like symptoms, which can be reduced by taking indometha-
cin or paracetamol before the infusion [47].
4.2.3. Bevacizumab
Bevacizumab (Avastin®, Genentech, Inc., a member of the Roche Group) was approved as 
an i.v. infusion in 2014 by the Food and Drug Administration (FDA) and by EMA in combi-
nation with paclitaxel, topotecan, or pegylated liposomal doxorubicin, for the treatment of 
adult patients with recurrent epithelial ovarian cancer that is resistant to platinum-containing 
chemotherapy. Bevacizumab is a humanised monoclonal antibody directed against vascu-
lar endothelial growth factor (VEGF). Bevacizumab binds to VEGF and thereby prevents 
the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface 
of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisa-
tion of tumours and inhibits the formation of a new tumour vasculature and thereby inhibits 
tumour growth. Interestingly, the delay of tumour growth induced by anti-VEGF antibody 
was mainly attributed to the blockage of ascites development and vascular permeability and 
to a lesser degree to the inhibition of VEGF-induced angiogenesis [7].
Approval of bevacizumab in the USA and EU was based on results of a phase III AURELIA 
study that involved 361 women with recurrent, platinum-resistant OC, who received either 
chemotherapy or bevacizumab in combination with chemotherapy. In the subgroup of 
patients with ascites at baseline, the absence of paracentesis after the first bevacizumab dose 
suggests that adding bevacizumab to chemotherapy improved the control of ascites [48]. 
Bevacizumab has been associated with serious (but rare) side effects, and the use of bevaci-
zumab remains significantly more expensive than cytotoxic therapies. The identification of 
predictive clinical and biological factors that could be utilised to select patients with a greater 
likelihood of clinical benefit therefore remains a high priority. Using data from Phase III trial 
GOG218 (Gynaecologic Oncology Group), ascites as a prognostic factor and as a predictor of 
efficacy for bevacizumab in advanced OC was investigated. In multivariate survival analysis, 
ascites was prognostic of poor overall survival (OS) but not progression-free survival (PFS). 
In predictive analysis, patients without ascites treated with bevacizumab had no significant 
improvement in either PFS or OS, whereas patients with ascites treated with bevacizumab 
had significantly improved PFS (p < 0.001) and OS (p = 0.014). These findings support the 
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plausible biologic rational that patients with malignant ascites have cancer with a pheno-
type representative of the initiation phase of angiogenesis and are therefore more likely to 
respond to anti-VEGF therapy. If these findings could be validated through a similar analysis 
of data from one or more independent randomised phase III trials, the clinical determination 
of malignant ascites could be a simple and cost-effective way of selecting patients with the 
greatest probability of benefit from bevacizumab. However, it is possible that volume of asci-
tes could be a more robust predictor of the degree of benefit from VEGF-targeted therapy [49].
Intraperitoneal administration of bevacizumab has also been explored, although only very 
few OC patients with malignant ascites have received this route of administration. In all 
patients, ascites resolved after a single i.p. dose (5 mg/kg) without re-accumulation or repeat 
paracentesis over a median observation period >2 months. Moreover, no grade 2–5 adverse 
events were observed [50]. To evaluate the great potential that preclinical data and clinical 
case reports have suggested for i.p. administration of bevacizumab, clinical trials should 
be undertaken regarding the safety of treatment, specifically for the palliation of ascites. 
Bevacizumab may have the potential advantage so that it could be used in patients with 
reduced performance [47].
4.2.4. Aflibercept (VEGF-TRAP)
Aflibercept (Zaltrap®, Sanofi-Aventis group) was approved for the treatment of adult meta-
static colorectal cancer that is resistant or has progressed after an oxalipatin-containing regi-
men. Aflibercept, also known as VEGF trap (it binds to VEGF trapping it and inhibiting it) 
in the scientific literature, is a fusion protein, comprising a portion of human VEGF receptor 
Fit-1 (VEGFR-1) + KDR (VEGFR-2) extracellular domains fused to the Fc-portion of human 
IgG. Aflibercept binds to VEGF-A, VEGF-B and placental growth factor (PIGF). By acting as a 
ligand trap, aflibercept prevents binding of endogenous ligands to their cognate receptors and 
thereby blocks receptor-mediated signalling. VEGF-A acts via VEGFR-1 and VEGFR-2 pres-
ent on the surface of endothelial cells. PIGF and VEGF-B bind only to VEGFR-1, which is also 
present on the surface of leucocytes. Excessive activation of receptors by VEGF-A can result 
in pathological neovascularisation and excessive vascular permeability. PIGF is also linked 
to pathological neovascularisation and recruitment of inflammatory cells into tumours [51]. 
In addition to the approved indication, aflibercept has demonstrated the ability to reduce the 
formation of ascites in patients with advanced epithelial OC [10, 52, 53]. In pre-clinical xeno-
graft models, aflibercept inhibited tumour growth, angiogenesis, reduced blood vessel density 
and inhibited metastases [10]. The safety and efficacy of aflibercept, administrated i.v. at a 
dosage of 4 mg/kg every 2 weeks, was tested in two-phase II clinical trials in chemoresistant 
advanced OC patients with recurrent symptomatic ascites [52, 53]. In a randomised, double 
blind, placebo-controlled, parallel trial, 29 patients were treated. The mean time to paracente-
sis was significantly (p = 0.0019) longer in the aflibercept arm (55.1 days) than in the placebo 
arm (23.3 days). Two patients receiving aflibercept did not need paracentesis for a period of 
6 months. The most common grade 3 or 4 adverse effects were dyspnea, fatigue or asthenia, 
and dehydration. The frequency of fatal gastrointestinal perforation was higher with afliber-
cept (three-bowel perforation) than with the placebo. In spite of the effectiveness of afliber-
cept in the reduction of malignantascites, the authors acknowledge that the limitation of this 
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treatment is the risk of significant morbidity associated with bowel perforation in patients with 
very advanced OC. Thus, the advantages of aflibercept over bevacizumab are unclear [53].
4.2.5. Matrix metalloproteinase inhibitors (MMPIs)
MMPs, mainly MMP9, play a role in the release of biologically active VEGF and, conse-
quently, play a role in the formation of ascites. Batistamat, a potent reversible inhibitor of a 
broad spectrum of MMP, has been developed and has been shown to resolve ascites when 
given i.p. to mice ascites secondary to an ovarian carcinoma xenograft; treatment was accom-
panied by a 6.5-fold increase in survival [54]. Sixteen patients with OC (out of 23 patients) 
were included in a Phase I study of i.p. administration of batistamat after drainage of ascites. 
Patients acquired a predicted survival of 1 month or more. Of the 23 patients in the study, 16 
did not require redrainage within 28 days of the initial treatment. Five of the 23 patients nei-
ther reaccumulated ascites nor died up to 112 days after dosing. Seven patients died without 
reaccumulating ascites. Adverse effects considered at least possibly related to the treatment 
occurred in 16 patients, the most common of which were fatigue, fever, vomiting and abdomi-
nal pain [46]. MMP inhibitors may warrant further study.
4.2.6. Intraperitoneal chemotherapy
Intraperitoneal chemotherapy is an effective way to palliate malignant ascites. By destroying 
the surface cancer, it induces a progressive fibrotic process, which will prevent the forma-
tion of fluid. If the sclerotic process is not complete, it may produce fluid loculation, which 
will interfere with uniform drug distribution, may cause obstructions and makes subsequent 
paracentesis difficult and risky [29]. Intraperitoneal therapy with cisplatin has been evaluated 
for the first-line treatment of optimal debulked OC patients with FIGO stage III. Despite a 
16-month survival advantage, the catheter-related complications rate was 34%, and only 42% 
of women in the trial completed six cycles of chemotherapy [46].
The procedure called intraperitoneal hyperthermic chemotherapy (HIPEC) is an attempt to 
increase the cytotoxicity of selected cytotoxic drugs by a hyperthermic medium (40.5–43°C), 
thereby improving tissue penetration and reducing drug resistance. The primary objective 
is an increase of PFS and OS, not the control of ascites itself [47]. Finally, aggressive cytore-
ductive surgery combined with laparoscopic installation of HIPEC is reserved for selected 
patients with malignant ascites. In well-selected patients, results are encouraging, and this 
procedure not only controls ascites, but prolongation of OS is possible [29].
Laparoscopic installation of HIPEC has been recently reported as an option to treat resistant 
malignant ascites not suitable for surgery. The biggest series published, which also included 
patients with OC, was by Valle et al. [55], who achieved complete remission of ascites in 94% 
of 52 patients after 1 month of follow-up. There were no complications of the procedure, dem-
onstrating the feasibility and safety of this technique [55].
4.2.7. Diuretics
Some patients with liver metastasis and malignant ascites have raised plasma renin concen-
trations, and these patients showed a good response to aldosterone competitive antagonist 
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spironolactone, which decreases reabsorption of water and sodium in the renal collecting 
duct. Packros et al. [56] found that 13 of 15 patients treated with increasing doses of spirono-
lactone had a good response, with eight remaining free of ascites until death. Renin levels 
were raised in all of these patients [56].
5. Role of ascites in translational science
Ascites is often therapeutically removed from patients and is therefore an available source of 
valuable tumour material. Representing the local tumour environment, ascites is composed of 
cellular and acellular components. In addition to tumour cells present, either as single cells or as 
spheroids, the cellular component of ascites is composed of stromal cells, including fibroblasts, 
mesothelial cells, endothelial cells, adipocytes and inflammatory cells. Cells in ascites commu-
nicate with each other through acellular components, including cytokines, proteins, metabolites 
and exosomes. All these components work in coordination to create a tumour-friendly micro-
environment. Better knowledge of the tumour microenvironment represented by ascites would 
thus certainly help to overcome the limitations of current anticancer treatments [23].
Targeting ascites components that cause immunosuppression of T-cells is an interesting 
future therapeutic option. T-cells present in ovarian tumour ascites do not respond properly 
to stimulation via the T-cell receptor. Since these T-cells were assayed in the absence of ascites, 
they gained their normal function, but when ascites was added to T-cells, this effect was rap-
idly reversed. This might explain why human tumours grow despite the presence of T-cells 
and other cells of immunological response [10].
In the study by Latifi et al. [57], it was demonstrated that cells in malignant ascites belong to two 
types of tumour cells, adherent cells (expressed mesenchymal features) and non-adherent cells 
with an epithelial phenotype, as expressed by EpCAM and cytokeratin 7. Patients with chemo-
resistant tumours had more tumorogenic, non-adherent cells in the ascites than non-tumoro-
genic adherent cells. Non-adherent cells featured increased mRNA expression of cancer stem 
cell-associated genes [10]. Since catumaxomab selectively kills epithelial tumour cells belong-
ing to the non-adherent cell type, this might explain why it is beneficial for patients with OC.
Ascites is highly attractive as a source for biomarker discovery study. The concentrations of 
cancer-associated soluble factors are usually much higher in ascites than in serum [47, 58]. 
Moreover, investigation of the relationship between biomarker concentrations in ascites and 
serum in OC patients may help elucidate whether concentration changes in the local environ-
ment can be detected with a blood test [58].
6. Conclusions
The development of malignant ascites is probably dependent on a combination of factors, 
which disrupts the normal regulation of intraperitoneal fluid flow and the maintenance of a 
steady state in the peritoneal cavity. Each factor plays a greater or lesser role in each individ-
ual patient, so the results of available treatment alternatives are inconsistent. In advanced OC, 
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palliation of symptomatic patients is the foremost goal, and elimination of fluid accumulation in 
a patient with these symptoms will certainly improve the patient’s quality of life and may even 
prolong survival. However, effective palliation of malignant ascites remains a difficult manage-
ment issue. Present treatments have been developed, particularly for malignant ascites, with 
the primary aim of prolonging the time until a need for subsequent paracentesis. Further clini-
cal trials are therefore necessary in order to investigate the influence on ascites-triggered inter-
vention not only for symptomatic relief but also for the prolongation of both PFS and OS. For 
the use of targeted therapeutics in malignant ascites (catumaxomab, bevacizumab, aflibercept), 
it is mandatory to select patients carefully and to identify their risk factors so that the incidence 
of adverse effects can be minimised. The identification of predictive clinical and biological fac-
tors that could be utilised to select patients with a greater likelihood of clinical benefit remains a 
high priority. With advances in our understanding of malignant ascites pathophysiology, more 
effective treatment strategies for malignant ascites and ovarian cancer will emerge in the future.
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